| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 96 | 2023 | 151 | 14.680 |
Why?
|
| Antirheumatic Agents | 12 | 2023 | 33 | 2.750 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2023 | 52 | 2.530 |
Why?
|
| Immunosuppressive Agents | 7 | 2020 | 72 | 2.290 |
Why?
|
| Rheumatology | 7 | 2021 | 15 | 2.060 |
Why?
|
| Genetic Predisposition to Disease | 38 | 2016 | 528 | 1.930 |
Why?
|
| Middle Aged | 64 | 2023 | 9642 | 1.680 |
Why?
|
| Female | 104 | 2023 | 19873 | 1.670 |
Why?
|
| Fibromyalgia | 4 | 2016 | 11 | 1.660 |
Why?
|
| Humans | 138 | 2023 | 34853 | 1.650 |
Why?
|
| Puerto Rico | 22 | 2023 | 1352 | 1.590 |
Why?
|
| Polymorphism, Single Nucleotide | 39 | 2017 | 638 | 1.560 |
Why?
|
| Rheumatic Diseases | 3 | 2015 | 9 | 1.550 |
Why?
|
| Hydroxychloroquine | 8 | 2021 | 15 | 1.520 |
Why?
|
| Severity of Illness Index | 18 | 2023 | 608 | 1.510 |
Why?
|
| Methylprednisolone | 6 | 2018 | 13 | 1.470 |
Why?
|
| Lupus Nephritis | 11 | 2014 | 22 | 1.430 |
Why?
|
| Adult | 76 | 2023 | 11034 | 1.430 |
Why?
|
| Polyarteritis Nodosa | 2 | 2021 | 4 | 1.420 |
Why?
|
| Cyclophosphamide | 6 | 2021 | 52 | 1.390 |
Why?
|
| Diabetes Mellitus | 4 | 2021 | 465 | 1.240 |
Why?
|
| Male | 84 | 2023 | 18870 | 1.160 |
Why?
|
| Chikungunya virus | 3 | 2022 | 16 | 1.030 |
Why?
|
| Treatment Outcome | 11 | 2023 | 1349 | 1.000 |
Why?
|
| Disease Progression | 11 | 2023 | 580 | 0.990 |
Why?
|
| Scleroderma, Systemic | 2 | 2014 | 17 | 0.960 |
Why?
|
| Vasculitis | 2 | 2013 | 4 | 0.910 |
Why?
|
| Cryoglobulinemia | 2 | 2013 | 3 | 0.910 |
Why?
|
| Cohort Studies | 30 | 2023 | 1422 | 0.870 |
Why?
|
| Diabetes Complications | 2 | 2021 | 91 | 0.870 |
Why?
|
| Elbow Joint | 1 | 2022 | 2 | 0.870 |
Why?
|
| Arthritis, Infectious | 1 | 2021 | 6 | 0.810 |
Why?
|
| Back Pain | 1 | 2021 | 19 | 0.800 |
Why?
|
| Abdominal Pain | 2 | 2021 | 24 | 0.800 |
Why?
|
| Prednisone | 7 | 2022 | 26 | 0.790 |
Why?
|
| Haplotypes | 24 | 2015 | 152 | 0.790 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 1 | 0.790 |
Why?
|
| Venous Thrombosis | 5 | 2014 | 27 | 0.760 |
Why?
|
| Retinopathy of Prematurity | 1 | 2020 | 25 | 0.750 |
Why?
|
| Comorbidity | 8 | 2020 | 606 | 0.740 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 2561 | 0.740 |
Why?
|
| Glucocorticoids | 4 | 2013 | 80 | 0.700 |
Why?
|
| Case-Control Studies | 18 | 2021 | 1056 | 0.690 |
Why?
|
| Multivariate Analysis | 16 | 2015 | 570 | 0.680 |
Why?
|
| Fatigue | 4 | 2021 | 79 | 0.670 |
Why?
|
| Arthralgia | 2 | 2022 | 10 | 0.660 |
Why?
|
| Young Adult | 22 | 2022 | 4012 | 0.660 |
Why?
|
| Arthritis, Gouty | 1 | 2018 | 1 | 0.650 |
Why?
|
| Sacroiliac Joint | 1 | 2018 | 3 | 0.650 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 6 | 0.650 |
Why?
|
| Colchicine | 1 | 2018 | 15 | 0.650 |
Why?
|
| HLA Antigens | 2 | 2017 | 19 | 0.640 |
Why?
|
| Arthritis | 1 | 2018 | 16 | 0.640 |
Why?
|
| Genetic Load | 1 | 2017 | 1 | 0.630 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2017 | 137 | 0.620 |
Why?
|
| Hepatic Artery | 1 | 2017 | 2 | 0.610 |
Why?
|
| Thrombocytopenia | 4 | 2012 | 21 | 0.610 |
Why?
|
| Anemia, Hemolytic | 3 | 2012 | 8 | 0.610 |
Why?
|
| Aged | 15 | 2023 | 6448 | 0.600 |
Why?
|
| Myositis | 2 | 2014 | 7 | 0.600 |
Why?
|
| Alleles | 18 | 2018 | 284 | 0.590 |
Why?
|
| Longitudinal Studies | 23 | 2023 | 841 | 0.590 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2013 | 3 | 0.590 |
Why?
|
| Electroconvulsive Therapy | 1 | 2016 | 17 | 0.580 |
Why?
|
| Myositis, Inclusion Body | 1 | 2016 | 2 | 0.580 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2016 | 2 | 0.570 |
Why?
|
| Leg Ulcer | 2 | 2013 | 7 | 0.560 |
Why?
|
| Warfarin | 2 | 2013 | 59 | 0.550 |
Why?
|
| Diphosphonates | 2 | 2014 | 10 | 0.550 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 3 | 0.550 |
Why?
|
| Azathioprine | 1 | 2015 | 5 | 0.540 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2015 | 18 | 0.540 |
Why?
|
| Anticoagulants | 2 | 2013 | 97 | 0.540 |
Why?
|
| Kidney Diseases | 4 | 2011 | 159 | 0.540 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 22 | 0.540 |
Why?
|
| United States | 27 | 2021 | 3894 | 0.540 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 77 | 0.540 |
Why?
|
| Memory Disorders | 1 | 2016 | 65 | 0.530 |
Why?
|
| Polymorphism, Genetic | 4 | 2018 | 165 | 0.530 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2015 | 2 | 0.530 |
Why?
|
| Insurance, Health | 2 | 2013 | 120 | 0.530 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 5 | 0.530 |
Why?
|
| Cardiac Tamponade | 1 | 2015 | 4 | 0.530 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2014 | 1 | 0.520 |
Why?
|
| Mesentery | 1 | 2014 | 9 | 0.520 |
Why?
|
| Bronchial Fistula | 1 | 2014 | 2 | 0.520 |
Why?
|
| Pleural Diseases | 1 | 2014 | 2 | 0.520 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 206 | 0.520 |
Why?
|
| Genotype | 22 | 2015 | 641 | 0.500 |
Why?
|
| Bursitis | 1 | 2014 | 2 | 0.500 |
Why?
|
| Fractures, Spontaneous | 1 | 2014 | 6 | 0.490 |
Why?
|
| Dermatomyositis | 1 | 2014 | 6 | 0.490 |
Why?
|
| Endocarditis | 1 | 2014 | 11 | 0.490 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2014 | 21 | 0.490 |
Why?
|
| Patients | 1 | 2014 | 15 | 0.480 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2013 | 5 | 0.470 |
Why?
|
| Arm | 1 | 2013 | 25 | 0.470 |
Why?
|
| Osteonecrosis | 1 | 2013 | 5 | 0.470 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2013 | 9 | 0.460 |
Why?
|
| Polyneuropathies | 1 | 2013 | 10 | 0.460 |
Why?
|
| Genetic Loci | 6 | 2013 | 70 | 0.460 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 10 | 0.460 |
Why?
|
| Complex Mixtures | 1 | 2012 | 7 | 0.450 |
Why?
|
| Hand | 1 | 2013 | 23 | 0.450 |
Why?
|
| Nitrofurantoin | 1 | 2012 | 1 | 0.450 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2012 | 1 | 0.450 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2012 | 2 | 0.450 |
Why?
|
| Osteoarthritis | 1 | 2013 | 17 | 0.450 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 222 | 0.450 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 54 | 0.450 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 53 | 0.450 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 64 | 0.450 |
Why?
|
| Managed Care Programs | 1 | 2013 | 35 | 0.440 |
Why?
|
| Obesity | 4 | 2016 | 965 | 0.440 |
Why?
|
| Risk Factors | 23 | 2022 | 3414 | 0.440 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 36 | 0.430 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 32 | 0.430 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2012 | 9 | 0.420 |
Why?
|
| Health Literacy | 1 | 2014 | 100 | 0.420 |
Why?
|
| Hip Fractures | 1 | 2011 | 26 | 0.410 |
Why?
|
| Thrombosis | 5 | 2014 | 61 | 0.410 |
Why?
|
| Internship and Residency | 1 | 2013 | 121 | 0.410 |
Why?
|
| Antibodies, Antinuclear | 5 | 2016 | 20 | 0.390 |
Why?
|
| Dietary Supplements | 1 | 2012 | 196 | 0.390 |
Why?
|
| Logistic Models | 8 | 2017 | 894 | 0.390 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 211 | 0.390 |
Why?
|
| Quality of Life | 6 | 2023 | 459 | 0.370 |
Why?
|
| Autoantibodies | 5 | 2022 | 103 | 0.370 |
Why?
|
| Depression | 1 | 2016 | 664 | 0.370 |
Why?
|
| Adolescent | 17 | 2023 | 5035 | 0.360 |
Why?
|
| Blood Sedimentation | 2 | 2007 | 5 | 0.360 |
Why?
|
| Angiography | 2 | 2021 | 15 | 0.350 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 217 | 0.330 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 42 | 0.310 |
Why?
|
| DNA-Binding Proteins | 6 | 2014 | 522 | 0.310 |
Why?
|
| Fever | 2 | 2021 | 57 | 0.310 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2007 | 2 | 0.310 |
Why?
|
| Health Services | 1 | 2008 | 53 | 0.310 |
Why?
|
| Thrombocytosis | 1 | 2007 | 5 | 0.310 |
Why?
|
| Giant Cell Arteritis | 1 | 2007 | 1 | 0.310 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 224 | 0.300 |
Why?
|
| Anemia | 1 | 2007 | 45 | 0.300 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 5 | 0.300 |
Why?
|
| Acetylcarnitine | 1 | 2006 | 8 | 0.300 |
Why?
|
| STAT1 Transcription Factor | 2 | 2018 | 26 | 0.300 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 14 | 0.290 |
Why?
|
| Lymphopenia | 1 | 2006 | 15 | 0.290 |
Why?
|
| Mannose-Binding Lectin | 1 | 2006 | 5 | 0.290 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 38 | 0.290 |
Why?
|
| Prevalence | 7 | 2014 | 1425 | 0.290 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 964 | 0.270 |
Why?
|
| Primary Health Care | 1 | 2008 | 283 | 0.260 |
Why?
|
| Sex Factors | 6 | 2014 | 859 | 0.260 |
Why?
|
| Odds Ratio | 5 | 2014 | 517 | 0.260 |
Why?
|
| Interferon Regulatory Factors | 2 | 2014 | 15 | 0.240 |
Why?
|
| Methotrexate | 2 | 2016 | 20 | 0.220 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 424 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 468 | 0.220 |
Why?
|
| Elbow | 1 | 2022 | 4 | 0.220 |
Why?
|
| Synovial Membrane | 1 | 2022 | 4 | 0.220 |
Why?
|
| Chronic Disease | 2 | 2021 | 469 | 0.220 |
Why?
|
| Linkage Disequilibrium | 8 | 2016 | 58 | 0.210 |
Why?
|
| Interleukin-10 | 2 | 2013 | 69 | 0.200 |
Why?
|
| Molecular Motor Proteins | 2 | 2011 | 8 | 0.200 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 19 | 0.200 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2012 | 6 | 0.200 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2012 | 6 | 0.200 |
Why?
|
| Antibodies | 2 | 2015 | 135 | 0.200 |
Why?
|
| Intestines | 1 | 2021 | 63 | 0.200 |
Why?
|
| Minority Health | 1 | 2021 | 81 | 0.200 |
Why?
|
| Vaccination | 1 | 2023 | 259 | 0.200 |
Why?
|
| Chromosomes, Human, X | 2 | 2012 | 14 | 0.200 |
Why?
|
| Time Factors | 8 | 2021 | 1681 | 0.190 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 104 | 0.190 |
Why?
|
| Retrospective Studies | 2 | 2020 | 1961 | 0.190 |
Why?
|
| Prognosis | 6 | 2021 | 707 | 0.190 |
Why?
|
| RNA, Messenger | 2 | 2023 | 1152 | 0.190 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 68 | 0.190 |
Why?
|
| Age of Onset | 3 | 2017 | 98 | 0.190 |
Why?
|
| C-Reactive Protein | 4 | 2009 | 147 | 0.190 |
Why?
|
| Ophthalmology | 1 | 2020 | 28 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 137 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 48 | 0.180 |
Why?
|
| Genetic Association Studies | 7 | 2015 | 102 | 0.180 |
Why?
|
| Chromosome Mapping | 4 | 2013 | 159 | 0.180 |
Why?
|
| Proportional Hazards Models | 6 | 2011 | 423 | 0.180 |
Why?
|
| Genome-Wide Association Study | 4 | 2016 | 271 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 187 | 0.170 |
Why?
|
| Phenotype | 8 | 2014 | 650 | 0.170 |
Why?
|
| STAT4 Transcription Factor | 1 | 2018 | 3 | 0.170 |
Why?
|
| HIV Infections | 2 | 2012 | 2207 | 0.170 |
Why?
|
| Epidural Abscess | 1 | 2018 | 1 | 0.160 |
Why?
|
| Gout Suppressants | 1 | 2018 | 5 | 0.160 |
Why?
|
| Decompression, Surgical | 1 | 2018 | 6 | 0.160 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 32 | 0.160 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 14 | 0.160 |
Why?
|
| Sequence Deletion | 1 | 2017 | 87 | 0.150 |
Why?
|
| Gene Frequency | 6 | 2013 | 155 | 0.150 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 2013 | 5 | 0.150 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2014 | 8 | 0.150 |
Why?
|
| Low Back Pain | 1 | 2018 | 86 | 0.150 |
Why?
|
| Minority Groups | 1 | 2021 | 537 | 0.150 |
Why?
|
| Texas | 6 | 2009 | 299 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2018 | 206 | 0.140 |
Why?
|
| Receptors, IgG | 2 | 2014 | 48 | 0.140 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 2 | 0.140 |
Why?
|
| Exons | 2 | 2006 | 80 | 0.140 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 232 | 0.140 |
Why?
|
| Cytokines | 2 | 2012 | 569 | 0.140 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2012 | 2 | 0.140 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2015 | 8 | 0.130 |
Why?
|
| Age Factors | 5 | 2010 | 1007 | 0.130 |
Why?
|
| Penicillamine | 1 | 2014 | 2 | 0.130 |
Why?
|
| Fat Necrosis | 1 | 2014 | 3 | 0.130 |
Why?
|
| Pericardium | 1 | 2015 | 15 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 484 | 0.130 |
Why?
|
| Receptors, Complement 3d | 1 | 2014 | 3 | 0.130 |
Why?
|
| Raynaud Disease | 1 | 2014 | 10 | 0.130 |
Why?
|
| beta Karyopherins | 1 | 2014 | 4 | 0.130 |
Why?
|
| Educational Status | 2 | 2014 | 295 | 0.130 |
Why?
|
| Socioeconomic Factors | 5 | 2012 | 1003 | 0.130 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2014 | 25 | 0.120 |
Why?
|
| Leptin | 1 | 2015 | 115 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2014 | 7 | 0.120 |
Why?
|
| Proteinuria | 2 | 2011 | 48 | 0.120 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2013 | 2 | 0.120 |
Why?
|
| Biopsy | 1 | 2014 | 151 | 0.120 |
Why?
|
| Interleukin-2 | 2 | 2011 | 87 | 0.120 |
Why?
|
| Social Class | 2 | 2014 | 228 | 0.120 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2013 | 14 | 0.120 |
Why?
|
| Echocardiography | 1 | 2015 | 144 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2014 | 42 | 0.120 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 27 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2013 | 1 | 0.120 |
Why?
|
| Bacteremia | 1 | 2014 | 31 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2016 | 287 | 0.120 |
Why?
|
| Immunoglobulin A | 1 | 2013 | 58 | 0.120 |
Why?
|
| Deglutition Disorders | 1 | 2014 | 18 | 0.120 |
Why?
|
| Thrombophlebitis | 1 | 2013 | 2 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2013 | 429 | 0.120 |
Why?
|
| Talus | 1 | 2013 | 1 | 0.120 |
Why?
|
| Fibula | 1 | 2013 | 2 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 184 | 0.120 |
Why?
|
| Bone Density | 1 | 2014 | 76 | 0.120 |
Why?
|
| Infant | 1 | 2017 | 1014 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2013 | 37 | 0.120 |
Why?
|
| Tibia | 1 | 2013 | 18 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 11 | 0.120 |
Why?
|
| Indians, North American | 2 | 2012 | 145 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2013 | 93 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2014 | 99 | 0.120 |
Why?
|
| Hemostasis | 1 | 2013 | 6 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 165 | 0.110 |
Why?
|
| Office Visits | 1 | 2013 | 22 | 0.110 |
Why?
|
| Indians, South American | 1 | 2012 | 5 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 80 | 0.110 |
Why?
|
| Weight Loss | 1 | 2014 | 124 | 0.110 |
Why?
|
| Mixed Function Oxygenases | 1 | 2013 | 29 | 0.110 |
Why?
|
| Plasmapheresis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2012 | 5 | 0.110 |
Why?
|
| Income | 1 | 2014 | 135 | 0.110 |
Why?
|
| Health Status | 2 | 2007 | 356 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 48 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2017 | 1318 | 0.110 |
Why?
|
| Plasma | 1 | 2012 | 29 | 0.110 |
Why?
|
| Acute Disease | 1 | 2012 | 141 | 0.110 |
Why?
|
| Poverty | 2 | 2013 | 316 | 0.110 |
Why?
|
| Egg Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 8 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 142 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 15 | 0.110 |
Why?
|
| Cardiovascular Diseases | 3 | 2009 | 628 | 0.110 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 15 | 0.110 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 207 | 0.110 |
Why?
|
| Apolipoproteins | 1 | 2011 | 19 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 70 | 0.100 |
Why?
|
| Radiography | 1 | 2011 | 75 | 0.100 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 22 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 491 | 0.100 |
Why?
|
| Vitamin D | 1 | 2014 | 176 | 0.100 |
Why?
|
| DNA Damage | 1 | 2014 | 341 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Complement C4 | 1 | 2011 | 5 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 43 | 0.100 |
Why?
|
| Complement Factor H | 1 | 2011 | 5 | 0.100 |
Why?
|
| Child | 2 | 2017 | 2875 | 0.100 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 203 | 0.100 |
Why?
|
| Autoimmune Diseases | 2 | 2014 | 55 | 0.100 |
Why?
|
| Interferons | 1 | 2011 | 34 | 0.100 |
Why?
|
| Community Health Services | 1 | 2013 | 175 | 0.100 |
Why?
|
| Interleukins | 1 | 2011 | 28 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 213 | 0.100 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 5 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 550 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 15 | 0.100 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 14 | 0.100 |
Why?
|
| DNA | 3 | 2014 | 549 | 0.100 |
Why?
|
| Kidney | 2 | 2013 | 322 | 0.100 |
Why?
|
| Protein Binding | 4 | 2015 | 913 | 0.100 |
Why?
|
| Calcium | 1 | 2014 | 445 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 56 | 0.100 |
Why?
|
| Interferon Type I | 1 | 2010 | 17 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2021 | 288 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2010 | 32 | 0.090 |
Why?
|
| Demography | 2 | 2008 | 167 | 0.090 |
Why?
|
| Illness Behavior | 1 | 2009 | 3 | 0.090 |
Why?
|
| Hypertension | 2 | 2007 | 770 | 0.090 |
Why?
|
| Interleukin-21 Receptor alpha Subunit | 1 | 2009 | 1 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2011 | 154 | 0.090 |
Why?
|
| Alabama | 2 | 2005 | 46 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 287 | 0.090 |
Why?
|
| Klinefelter Syndrome | 1 | 2008 | 3 | 0.080 |
Why?
|
| DNA Replication | 1 | 2009 | 148 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2008 | 74 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2012 | 486 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 386 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 13 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2007 | 9 | 0.080 |
Why?
|
| Forms and Records Control | 1 | 2007 | 5 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2007 | 18 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2333 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 44 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 2007 | 18 | 0.080 |
Why?
|
| Acute-Phase Reaction | 1 | 2007 | 2 | 0.080 |
Why?
|
| Remission Induction | 1 | 2007 | 18 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 36 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2009 | 226 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2007 | 73 | 0.080 |
Why?
|
| Recurrence | 1 | 2007 | 125 | 0.070 |
Why?
|
| Heroin Dependence | 1 | 2006 | 23 | 0.070 |
Why?
|
| Chemokine CCL3 | 1 | 2006 | 13 | 0.070 |
Why?
|
| Chemokine CCL4 | 1 | 2006 | 18 | 0.070 |
Why?
|
| Intracranial Thrombosis | 1 | 2006 | 4 | 0.070 |
Why?
|
| Nephritis | 1 | 2006 | 6 | 0.070 |
Why?
|
| Mannose-Binding Lectins | 1 | 2006 | 14 | 0.070 |
Why?
|
| Pain | 1 | 2009 | 249 | 0.070 |
Why?
|
| Mexican Americans | 2 | 2007 | 177 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 528 | 0.070 |
Why?
|
| Cocaine-Related Disorders | 1 | 2006 | 84 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2007 | 56 | 0.070 |
Why?
|
| Lipoproteins, LDL | 1 | 2006 | 61 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2006 | 116 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 147 | 0.070 |
Why?
|
| Psychology | 1 | 2005 | 32 | 0.070 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2005 | 1 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2006 | 120 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2007 | 213 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2005 | 30 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2015 | 91 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 124 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 231 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 984 | 0.060 |
Why?
|
| Brazil | 1 | 2023 | 66 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2007 | 775 | 0.060 |
Why?
|
| Physical Examination | 1 | 2023 | 40 | 0.060 |
Why?
|
| Pedigree | 2 | 2016 | 64 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 531 | 0.060 |
Why?
|
| Introns | 2 | 2013 | 67 | 0.050 |
Why?
|
| Animals | 5 | 2022 | 14307 | 0.050 |
Why?
|
| Mice | 4 | 2015 | 5668 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 901 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2012 | 118 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2021 | 62 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2021 | 62 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 106 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 341 | 0.050 |
Why?
|
| Aging | 1 | 2005 | 639 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 181 | 0.050 |
Why?
|
| Base Sequence | 2 | 2012 | 932 | 0.050 |
Why?
|
| Clonal Anergy | 1 | 1999 | 5 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 328 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 1490 | 0.040 |
Why?
|
| Smoking | 1 | 2005 | 903 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1999 | 123 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 968 | 0.040 |
Why?
|
| Survival Rate | 2 | 2008 | 310 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2007 | 322 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 4 | 0.030 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 16 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 52 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 58 | 0.030 |
Why?
|
| Arteries | 1 | 2014 | 67 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 7 | 0.030 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 22 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 20 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 6 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 185 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 51 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 67 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 430 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 87 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 94 | 0.030 |
Why?
|
| Genome, Human | 1 | 2013 | 112 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2012 | 6 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 53 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2012 | 66 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2012 | 37 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 37 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2012 | 59 | 0.030 |
Why?
|
| Oral Ulcer | 1 | 2011 | 3 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 66 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 8 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 727 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2012 | 140 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2013 | 490 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 180 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 82 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 306 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2010 | 11 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 156 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 897 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 455 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 15 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 325 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 338 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 653 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 2009 | 14 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 44 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 1530 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 46 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 577 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 102 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 1353 | 0.020 |
Why?
|
| HLA-DQ Antigens | 1 | 2007 | 6 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2007 | 20 | 0.020 |
Why?
|
| snRNP Core Proteins | 1 | 2007 | 11 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2006 | 2 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 608 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 198 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2006 | 56 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2006 | 39 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 221 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 87 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 63 | 0.020 |
Why?
|
| Autoantigens | 1 | 2007 | 82 | 0.020 |
Why?
|
| Risk | 1 | 2007 | 256 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 111 | 0.020 |
Why?
|
| Homozygote | 1 | 2006 | 75 | 0.020 |
Why?
|
| Pneumonia | 1 | 2007 | 50 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1023 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1317 | 0.020 |
Why?
|
| Menopause | 1 | 2005 | 54 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 1442 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 407 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2004 | 111 | 0.020 |
Why?
|
| Behavior | 1 | 2004 | 32 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1149 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1999 | 67 | 0.010 |
Why?
|